Status: One Wales interim decision | ||
Using the agreed starting and stopping criteria, vedolizumab (Entyvio®) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response or non-response to anti-TNF treatment; for Crohn’s disease following loss of response or non-response to anti-TNF treatment and ustekinumab. The risks and benefits of the off-label use of vedolizumab (Entyvio®) for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. In February 2023 OWMAG recommended this treatment in NHS Wales, in April 2024 there was a review of the recommendation. OWMAG found nothing new that affects the original decision. Next review: this advice will be reviewed after 3 years or earlier if new evidence becomes available. |
||
|
||
Medicine details |
||
Medicine name | vedolizumab (Entyvio®) | |
Formulation | infusion | |
Reference number | OW24 | |
Indication | Treatment of inflammatory bowel disease in children and young people aged 6 to 17 years |
|
Company | Takeda UK Ltd | |
BNF chapter | Gastro-intestinal system | |
Submission type | One Wales | |
Status | One Wales interim decision | |
Advice number | OW24 | |
Date of issue | April 2023 | |
Date of last review | May 2024 |